Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine

Cellular Immunology

Volumn 265, Issue 1, 2010, Pages 65-73

  Kohler, M Eric ^a   Hallett, William H D ^a   Chen, Qing Rong ^b   Khan, Javed ^b   Johnson, Bryon D ^a   Orentas, Rimas J ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; CD8; Cellular immunity; Gene expression profiling; GSEA; Neuroblastoma; Stem cells; Tumor immunity

Indexed keywords

BASILIXIMAB; MESSENGER RNA; TUMOR VACCINE; CANCER VACCINE; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; ANIMAL; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; VACCINATION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; MICE; NEUROBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; STEM CELLS; SURVIVAL ANALYSIS; VACCINATION;

MUS;

EID: 77956171011     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.07.004     Document Type: Article

References (61)

1. Klaassen R.J., Trebo M.M., Koplewitz B.Z., Weitzman S.S., Calderwood S. High-risk neuroblastoma in Ontario: a report of experience from 1989-1995. J. Pediatr. Hematol. Oncol. 2003, 225:8-13.
2. Maris J.M., Hogarty M.D., Bagatell R., Cohn SL S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
3. Fish J.D., Grupp S.A. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008, 41:59-165.
4. Blattman J.N., Greenberg P.D. Cancer immunotherapy: a treatment for the masses. Science 2004, 305:200-205.
5. Mocellin S., Mandruzzato S., Bronte V., Lise M., Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol. 2004, 5:681-689.
6. + T cell differentiation. Cell 2002, 111:837-851.
7. + T cells during viral infection. J. Immunol. 2001, 166:795-799.
8. + T cell differentiation during viral infection. Immunity 2007, 27:393-405.
9. Mercado R., Vijh S., Allen S.E., Kerksiek K., Pilip I.M., Pamer E.G. Early programming of T cell populations responding to bacterial infection. J. Immunol. 2000, 165:6833-6839.
10. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2001, 2:415-422.
11. + T cell response. J. Exp. Med. 2006, 203:2135-2143.
12. Johnson B.D., Gershan J.A., Natalia N., Zujewski H., Weber J.J., Yan X., Orentas R.J. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. J. Immunother. 2005, 449-460.
13. Jing W., Orentas R.J., Johnson B.D. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol. Blood Marrow Transplant. 2007, 13:277-292.
14. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 2006, 176:1750-1758.
15. + T regulatory cells. J. Immunol. 2006, 176:3301-3305.
16. + regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J. Immunother. 2007, 30:203-214.
17. Johnson B.D., Yan X., Schauer D.W., Orentas R.J. Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell. Immunol. 2003, 222:15-26.
18. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 2001, 98:1-36.
19. Subramanian A., Tanayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
20. Sturn A., Quackenbush J., Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002, 18:207-208.
21. Prigione I., Corrias N.V., Airoldi I., Raffaghello L., Morandi F., Bocca P., Cocco C., Ferrone S., Pistoia V. Immunogenicity of human neuroblastoma. Ann. N.Y. Acad. Sci. 2004, 1028:69-80.
22. Yan X., Johnson B.D., Orentas R.J. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 2004, 112:105-116.
23. Orentas R.J., Kohler M.E., Johnson B.D. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin. Cancer Biol. 2006, 16:137-149.
24. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
25. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163:5211-5218.
26. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
27. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakamaya E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 1999, 59:3128-3133.
28. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
29. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 2002, 32:3267-3275.
30. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., Melton D.A. " Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002, 298:597-600.
31. Bocchia M., Bronte V., Colombo M.P., De Vincentis A., Di Nicola M., Forni G., Lanata L., Lemoli R.M., Massaia M., Rondelli D., Zanon P., Tura S. Antitumor vaccination: where we stand. Haematologica 2000, 85:1172-1206.
32. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borello I., Hwang L., Fein S., Pardoll D., Levitsky H H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 1998, 95:1178-1183.
33. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J.Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 1997, 18:493-497.
34. Finke J., Ferrone S., Frey A., Mufson A., Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today 1999, 20:158-160.
35. Cuenca A., Cheng F., Wang H., Brayer J., Horna P., Gu L., Bien H., Borello I.M., Levitsky H.I., Sotomayor E.M. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003, 63:9007-9015.
36. Levey D.L., Srivastava P.K. Alterations in T cells of cancer-bearers whence specificity?. Immunol. Today 1996, 365-368.
37. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258:1795-1798.
38. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., Bluestone J.A., Schreiber K. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 1997, 186:229-238.
39. Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 2001, 24:431-446.
40. Nanni P., Forni G., Lollini P.L. Cytokine gene therapy: hopes and pitfalls. Ann. Oncol. 1999, 10:261-266.
41. Teague T.K., Hildeman D., Kedl R.M., Mitchell T., Rees W., Schaefer B.C., Bender J., Kappler J., Marrack P. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc. Natl. Acad. Sci. USA 1999, 96:12691-12696.
42. Cheadle C., Fan J., Cho-Chung Y.S., Werner T., Ray J., Do L., Gorospe M., Becker K.G. Control of gene expression during T cell activation: alternate regulation of mRNA transcription and mRNA stability. BMC Genomics 2005, 6:75.
43. Cheadle C., Fan J., Cho-Chung Y.S., Werner T., Ray J., Do L., Gorospe M., Becker K.G. Stability regulation of mRNA and the control of gene expression. Ann. N.Y. Acad. Sci. 2005, 1058:196-204.
44. Northrop J.K., Thomas R.M., Wells A.D., Shen H. Epigenetic remodeling of the IL-2 and IFN-γ loci in memory CD8 T cells is influenced by CD4 T cells. J. Immunol. 2006, 177:1062-1069.
45. + T lymphocytes. J. Immunol. 1999, 162:5053-5057.
46. Chappell C., Beard C., Altman J., Jaenisch R., Jacob J. DNA methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion. J. Immunol. 2006, 176:4562-4572.
47. Diehn M., Alizadeh A.A., Rando O.J., Liu C.L., Stankunas K., Botstein D., Crabtree G.R., Brown P.O. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 2002, 99:11796-11801.
48. Chtanova T., Kemp R.A., Sutherland A.P., Ronchese F., Mackay C.R. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. J. Immunol. 2001, 167:3057-3063.
49. Chtanova T., Tangye S.G., Newton R., Frank N., Hodge M.R., Rolph M.S., Mackay C.R. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 2004, 173:68-78.
50. Riley J.L., Mao M., Kobayashi S., Biery M., Burchard J., Cavet G., Gregson B.P., June C.H., Linsley P.S. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. USA 2002, 99:11790-11795.
51. Carrabba M.G., Castelli C., Maeurer M.J., Squarcina P., Cova A., Pilla L., Renkvist N., Parmiani G., Rivoltini L. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 2003, 63:1560-1567.
52. + T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
53. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
54. Zheng Y., Collins S.L., Lutz M.A., Allen A.N., Kole T.P., Zarek P.E., Powell J.D. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 2007, 178:2163-2170.
55. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2002, 2:251-262.
56. Watt F.M., Hogan B.L. Out of Eden: stem cells and their niches. Science 2000, 287:1427-1430.
57. Williams M.A., Bevan M.J. Effector and memory CTL differentiation. Annu. Rev. Immunol. 2007, 25:171-192.
58. Luckey C.J., Bhattacharaya D., Goldrath A.W., Weissman I.L., Benoist C., Mathis D. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 2006, 103:3304-3309.
59. Joshi N.S., Nair N., Begum G., Joshi N.B., Sinkar V.P., Vora S. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
60. Wherry E.J., Barber D.L., Kaech S.M., Blattman J.N., Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 2004, 101:16004-16009.
61. + T cells. J. Clin. Invest. 2005, 115:1616-1626.